Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2010

Fluidigm and SABiosciences to Develop Pathway-Focused PCR Gene-Expression Panels

  • Fluidigm and SABiosciences are teaming up to create over 100 pathway-focused gene-expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System and its integrated fluidic circuits (IFCs). These kits are named the RT² Profiler™ PCR Arrays.
     
    Each reagent kit includes prealiquoted reagents and primers needed for synthesizing first-strand cDNA ready for preamplification and pathway-focused analysis. PCR arrays contain enough reagent to run five 96.96 Dynamic Array chips, and customized panels are also available.
     
    “SABiosciences’ solutions focusing on the analysis of pathways with real-time assay panel kits are an excellent fit to our products,” remarks Mike Lee, Fluidigm’s senior director of marketing. “The kits include 96 cataloged gene-expression assays, targeting genes in signal transduction, biological process, and disease-related pathways. The kits can provide a great solution for customers looking to lower start-up costs or that need prevalidated pathways for a new project.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »